Do analysts prefer MOR or ALLO?

Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 353.31%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Allogene Therapeutics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69

Is GPCR or ALLO more profitable?

Structure Therapeutics' return on equity of -24.91% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -24.91% -23.67% Allogene Therapeutics N/A -56.45% -40.36%

Does the media favor GPCR or ALLO?

In the previous week, Allogene Therapeutics had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for Structure Therapeutics. Allogene Therapeutics' average media sentiment score of 0.67 beat Structure Therapeutics' score of 0.33 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALLO or RLAY more profitable?

Relay Therapeutics' return on equity of -43.94% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Relay Therapeutics N/A -43.94% -40.11%

Does the media refer more to ALLO or RLAY?

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 4 articles in the media. Allogene Therapeutics' average media sentiment score of 0.67 beat Relay Therapeutics' score of 0.16 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALLO or ARQT?

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 4 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.68 beat Allogene Therapeutics' score of 0.67 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Allogene Therapeutics (ALLO) Competitors

$1.88 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$1.91 +0.03 (+1.60%)

As of 05:22 AM Eastern

Compare

ALLO vs. MOR, GPCR, ALMS, RLAY, and ARQT

Should you buy Allogene Therapeutics stock or one of its competitors? MarketBeat compares Allogene Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allogene Therapeutics include MorphoSys (MOR), Structure Therapeutics (GPCR), Alumis (ALMS), Relay Therapeutics (RLAY), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.

How does Allogene Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Allogene Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Allogene Therapeutics' return on equity of -56.45% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Allogene Therapeutics had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Allogene Therapeutics and 0 mentions for MorphoSys. Allogene Therapeutics' average media sentiment score of 0.67 beat MorphoSys' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Allogene Therapeutics	Positive

Allogene Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Allogene Therapeutics	$20K	32,444.10	-$190.89M	-$0.77	N/A

Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 353.31%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allogene Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats MorphoSys on 14 of the 17 factors compared between the two stocks.

How does Allogene Therapeutics compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Structure Therapeutics' return on equity of -24.91% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Allogene Therapeutics had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for Structure Therapeutics. Allogene Therapeutics' average media sentiment score of 0.67 beat Structure Therapeutics' score of 0.33 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics has higher earnings, but lower revenue than Allogene Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Allogene Therapeutics	$20K	32,444.10	-$190.89M	-$0.77	N/A

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Structure Therapeutics currently has a consensus price target of $109.25, suggesting a potential upside of 190.71%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 353.31%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Summary

Allogene Therapeutics beats Structure Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Allogene Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Alumis currently has a consensus target price of $40.30, suggesting a potential upside of 111.44%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 353.31%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Alumis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

83.6% of Allogene Therapeutics shares are held by institutional investors. 33.7% of Alumis shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alumis has a beta of -0.55, meaning that its share price is 155% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Allogene Therapeutics' return on equity of -56.45% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Allogene Therapeutics	N/A	-56.45%	-40.36%

In the previous week, Allogene Therapeutics had 4 more articles in the media than Alumis. MarketBeat recorded 4 mentions for Allogene Therapeutics and 0 mentions for Alumis. Allogene Therapeutics' average media sentiment score of 0.67 beat Alumis' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alumis	Neutral
Allogene Therapeutics	Positive

Allogene Therapeutics has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	101.04	-$243.32M	-$1.98	N/A
Allogene Therapeutics	$20K	32,444.10	-$190.89M	-$0.77	N/A

Summary

Allogene Therapeutics beats Alumis on 12 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Relay Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 4 articles in the media. Allogene Therapeutics' average media sentiment score of 0.67 beat Relay Therapeutics' score of 0.16 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relay Therapeutics' return on equity of -43.94% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Relay Therapeutics	N/A	-43.94%	-40.11%

Allogene Therapeutics has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	32,444.10	-$190.89M	-$0.77	N/A
Relay Therapeutics	$15.35M	168.75	-$276.48M	-$1.57	N/A

Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Allogene Therapeutics currently has a consensus price target of $8.52, indicating a potential upside of 353.31%. Relay Therapeutics has a consensus price target of $23.30, indicating a potential upside of 72.34%. Given Allogene Therapeutics' higher possible upside, equities analysts plainly believe Allogene Therapeutics is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Allogene Therapeutics and Relay Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Allogene Therapeutics compare to Arcutis Biotherapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Allogene Therapeutics presently has a consensus target price of $8.52, indicating a potential upside of 353.31%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 60.15%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

83.6% of Allogene Therapeutics shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Allogene Therapeutics and Allogene Therapeutics both had 4 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.68 beat Allogene Therapeutics' score of 0.67 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Arcutis Biotherapeutics has higher revenue and earnings than Allogene Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	32,444.10	-$190.89M	-$0.77	N/A
Arcutis Biotherapeutics	$376.07M	7.06	-$16.14M	-$0.03	N/A

Summary

Allogene Therapeutics beats Arcutis Biotherapeutics on 9 of the 16 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLO vs. The Competition

Export

Metric	Allogene Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$648.88M	$3.33B	$6.46B	$11.98B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-2.44	19.02	23.87	23.62
Price / Sales	32,444.10	304.24	513.32	111.43
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.45	7.97	10.38	6.66
Net Income	-$190.89M	$23.89M	$3.57B	$337.72M
7 Day Performance	-12.56%	-5.14%	-0.90%	-3.71%
1 Month Performance	-17.54%	2.54%	3.56%	0.97%
1 Year Performance	32.39%	36.80%	23.81%	25.35%

Allogene Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLO Allogene Therapeutics	2.9323 of 5 stars	$1.88 flat	$8.52 +353.3%	+32.4%	$648.88M	$20K	N/A	310	News Coverage Gap Down
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
GPCR Structure Therapeutics	2.8827 of 5 stars	$38.55 -2.0%	$109.25 +183.4%	+77.9%	$2.80B	N/A	N/A	136	Gap Up
ALMS Alumis	2.194 of 5 stars	$20.33 -5.9%	$40.30 +98.2%	+430.9%	$2.75B	$24.05M	N/A	N/A	Positive News High Trading Volume
RLAY Relay Therapeutics	2.5786 of 5 stars	$14.26 +1.5%	$23.30 +63.4%	+302.4%	$2.69B	$10.68M	N/A	330	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Competitors

ALLO vs. MOR, GPCR, ALMS, RLAY, and ARQT

How does Allogene Therapeutics compare to MorphoSys?

Summary

How does Allogene Therapeutics compare to Structure Therapeutics?

Summary

How does Allogene Therapeutics compare to Alumis?

Summary

How does Allogene Therapeutics compare to Relay Therapeutics?

Summary

How does Allogene Therapeutics compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Competitors

ALLO vs. MOR, GPCR, ALMS, RLAY, and ARQT

How does Allogene Therapeutics compare to MorphoSys?

Is MOR or ALLO more profitable?

Does the media refer more to MOR or ALLO?

Which has higher earnings and valuation, MOR or ALLO?

Do analysts prefer MOR or ALLO?

Which has more risk & volatility, MOR or ALLO?

Do insiders & institutionals hold more shares of MOR or ALLO?

Summary

How does Allogene Therapeutics compare to Structure Therapeutics?

Is GPCR or ALLO more profitable?

Does the media favor GPCR or ALLO?

Which has preferable earnings and valuation, GPCR or ALLO?

Do institutionals & insiders have more ownership in GPCR or ALLO?

Which has more volatility & risk, GPCR or ALLO?

Do analysts recommend GPCR or ALLO?

Summary

How does Allogene Therapeutics compare to Alumis?

Do analysts prefer ALMS or ALLO?

Do insiders and institutionals believe in ALMS or ALLO?

Which has more risk and volatility, ALMS or ALLO?

Is ALMS or ALLO more profitable?

Does the media favor ALMS or ALLO?

Which has stronger earnings & valuation, ALMS or ALLO?

Summary

How does Allogene Therapeutics compare to Relay Therapeutics?

Does the media refer more to ALLO or RLAY?

Is ALLO or RLAY more profitable?

Which has higher valuation and earnings, ALLO or RLAY?

Which has more volatility & risk, ALLO or RLAY?

Do analysts recommend ALLO or RLAY?

Do institutionals & insiders believe in ALLO or RLAY?

Summary

How does Allogene Therapeutics compare to Arcutis Biotherapeutics?

Which has more risk and volatility, ALLO or ARQT?

Do analysts recommend ALLO or ARQT?

Do institutionals and insiders believe in ALLO or ARQT?

Does the media refer more to ALLO or ARQT?

Is ALLO or ARQT more profitable?

Which has preferable earnings & valuation, ALLO or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools